# CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

> **NCT04700319** · EARLY_PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- CAR

## Interventions

- **DRUG:** CD19/CD20 CAR-T cell infusion

## Key facts

- **NCT ID:** NCT04700319
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-19
- **Primary completion:** 2021-05-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700319, "CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04700319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*